Beleodaq (belinostat)

P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Nov 2027

P2, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2027 --> Dec 2025

Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC-MS/MS, HPLC-UV, FTIR, TLC, NMR, and ESI-MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug-drug interactions.

P1, N=48, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P2, N=15, Completed, University of Miami | Active, not recruiting --> Completed

P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027

P1, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting

Our study established a NM-related gene signature closely linked to immune microenvironment and drug sensitivity, highlighting potential biomarkers and therapeutic targets for prognosis and personalized therapy in HNSCC.

P3, N=218, Recruiting, Dizal Pharmaceuticals

Regarding treatment, Belinostat, Dabrafenib, and Sorafenib showed higher sensitivity in the low-risk group, whereas Docetaxel demonstrated greater sensitivity in the high-risk category. This study offers a comprehensive analysis of the immune landscape characteristics and potential anticancer drugs in HCC based on PFRGs, providing valuable insights and novel perspectives for the treatment of HCC patients.

To target these epigenetic vulnerabilities, innovative carrier-free nano-epidrugs (siMBD-R NPs) are developed, incorporating first-line doxorubicin (DOX) with siRNA against METTL1 (siMETTL1), FDA-approved HDAC inhibitor belinostat (BEL), and DSPE-PEG2000-cRGD. In vivo studies demonstrate that siMBD-R NPs can significantly potentiate chemosensitivity, achieving an 81.5% relative increase in tumor inhibition, and can activate an immune response. This work highlights the potential benefits of leveraging dual-targeted epigenetic intervention to evoke osteosarcoma chemosensitization.

Finally, belinostat extended in vivo survival only in IDHmut glioma models, not in IDHmut GBM models. Our findings provide a mechanistic rationale for further studies of HDACi in IDHmut glioma patients, as well as the potential use of YAP/TAZ as a biomarker of HDACi sensitivity in cancers.